Dexcom [DXCM] vs Boston Scientific [BSX] Detailed Stock Comparison

Dexcom

NASDAQ
Loading...

Boston Scientific

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Dexcom wins in 6 metrics, Boston Scientific wins in 13 metrics, with 0 ties. Boston Scientific appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricDexcomBoston ScientificBetter
P/E Ratio (TTM)47.3957.40Dexcom
Price-to-Book Ratio10.186.33Boston Scientific
Debt-to-Equity Ratio100.2453.09Boston Scientific
PEG Ratio1.710.39Boston Scientific
EV/EBITDA27.8533.24Dexcom
Profit Margin (TTM)13.29%13.55%Boston Scientific
Operating Margin (TTM)18.37%18.63%Boston Scientific
EBITDA Margin (TTM)18.37%18.63%Boston Scientific
Return on Equity22.83%11.55%Dexcom
Return on Assets (TTM)6.08%5.39%Dexcom
Free Cash Flow (TTM)$630.70M$2.37BBoston Scientific
1-Year Return-2.45%13.82%Boston Scientific
Price-to-Sales Ratio (TTM)6.157.72Dexcom
Enterprise Value$25.71B$156.39BBoston Scientific
EV/Revenue Ratio5.988.46Dexcom
Gross Profit Margin (TTM)59.53%67.65%Boston Scientific
Revenue per Share (TTM)$11$13Boston Scientific
Earnings per Share (Diluted)$1.41$1.67Boston Scientific
Beta (Stock Volatility)1.490.66Boston Scientific
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Dexcom vs Boston Scientific Stock Performance Analysis

Loading Price Chart...

Dexcom
Boston Scientific
Dexcom Stock Overview | Boston Scientific Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dexcom0.54%-2.72%-10.58%-20.51%-2.49%-15.36%
Boston Scientific0.39%-1.96%-9.79%-7.15%-3.83%7.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dexcom-2.45%-34.95%-31.15%242.65%1,848.39%2,085.53%
Boston Scientific13.82%142.00%133.88%470.02%1,469.66%307.71%

News Based Sentiment: Dexcom vs Boston Scientific

Dexcom

News based Sentiment: MIXED

Dexcom experienced a month of conflicting signals. While Q2 earnings beat expectations and revenue grew, concerns about regulatory delays, product safety allegations, and analyst downgrades created significant volatility and uncertainty, making it a mixed bag for investors.

View Dexcom News Sentiment Analysis

Boston Scientific

News based Sentiment: POSITIVE

October brought a wave of positive signals for Boston Scientific, including increased institutional investment, raised price targets from multiple firms, and a promising long-range plan. While insider selling remains a point to watch, the overall narrative is one of strong growth potential and investor confidence.

View Boston Scientific News Sentiment Analysis

Performance & Financial Health Analysis: Dexcom vs Boston Scientific

MetricDXCMBSX
Market Information
Market Cap i$26.16B$142.83B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i8,183,61211,631,001
90 Day Avg. Volume i5,586,6579,170,397
Last Close$66.44$96.22
52 Week Range$57.52 - $93.25$80.64 - $109.50
% from 52W High-28.75%-12.13%
All-Time High$164.86 (Nov 15, 2021)$109.50 (Sep 09, 2025)
% from All-Time High-59.70%-12.13%
Growth Metrics
Quarterly Revenue Growth0.15%0.23%
Quarterly Earnings Growth0.25%1.46%
Financial Health
Profit Margin (TTM) i0.13%0.14%
Operating Margin (TTM) i0.18%0.19%
Return on Equity (TTM) i0.23%0.12%
Debt to Equity (MRQ) i100.2453.09
Cash & Liquidity
Book Value per Share (MRQ)$6.56$15.14
Cash per Share (MRQ)$7.47$0.36
Operating Cash Flow (TTM) i$987.70M$4.28B
Levered Free Cash Flow (TTM) i$425.12M$2.94B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Dexcom vs Boston Scientific

MetricDXCMBSX
Price Ratios
P/E Ratio (TTM) i47.3957.40
Forward P/E i32.9134.35
PEG Ratio i1.710.39
Price to Sales (TTM) i6.157.72
Price to Book (MRQ) i10.186.33
Market Capitalization
Market Capitalization i$26.16B$142.83B
Enterprise Value i$25.71B$156.39B
Enterprise Value Metrics
Enterprise to Revenue i5.988.46
Enterprise to EBITDA i27.8533.24
Risk & Other Metrics
Beta i1.490.66
Book Value per Share (MRQ) i$6.56$15.14

Financial Statements Comparison: Dexcom vs Boston Scientific

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)DXCMBSX
Revenue/Sales i$1.04B$4.66B
Cost of Goods Sold i$447.00M$1.45B
Gross Profit i$589.00M$3.21B
Research & Development i$145.20M$443.00M
Operating Income (EBIT) i$133.70M$937.00M
EBITDA i$219.00M$1.23B
Pre-Tax Income i$154.30M$805.00M
Income Tax i$48.90M$133.00M
Net Income (Profit) i$105.40M$672.00M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)DXCMBSX
Cash & Equivalents i$904.90M$725.00M
Total Current Assets i$4.55B$7.34B
Total Current Liabilities i$3.04B$5.06B
Long-Term Debt i$1.36B$10.93B
Total Shareholders Equity i$2.27B$22.45B
Retained Earnings i$1.70B$3.35B
Property, Plant & Equipment i$59.10M$448.00M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)DXCMBSX
Operating Cash Flow i$167.90M$513.00M
Capital Expenditures i$-87.00M$-187.00M
Free Cash Flow i$96.80M$277.00M
Debt Repayment iN/A$-1.31B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricDXCMBSX
Shares Short i13.14M19.02M
Short Ratio i3.182.76
Short % of Float i0.04%0.01%
Average Daily Volume (10 Day) i8,183,61211,631,001
Average Daily Volume (90 Day) i5,586,6579,170,397
Shares Outstanding i390.70M1.47B
Float Shares i389.52M1.48B
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.97%0.94%

Dividend Analysis & Yield Comparison: Dexcom vs Boston Scientific

MetricDXCMBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A